• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Molnupiravir and nirmatrelvir-ritonavir reduce mortality risk during post-acute COVID-19 phase.

作者信息

Wan Eric Yuk Fai, Wang Boyuan, Mathur Sukriti, Chan Cheyenne I Ying, Yan Vincent Ka Chun, Lai Francisco Tsz Tsun, Chui Celine Sze Ling, Li Xue, Wong Carlos King Ho, Li Philip Hei, Lau Chak Sing, Wong Ian Chi Kei, Chan Esther Wai Yin

机构信息

Centre for Safe Medication Practice and Research, Department of Pharmacology and Pharmacy, Li Ka Shing Faculty of Medicine, The University of Hong Kong, Hong Kong, China; Laboratory of Data Discovery for Health (D24H), Hong Kong Science and Technology Park, Hong Kong, China; Department of Family Medicine and Primary Care, School of Clinical Medicine, Li Ka Shing Faculty of Medicine, The University of Hong Kong, Hong Kong, China.

Department of Family Medicine and Primary Care, School of Clinical Medicine, Li Ka Shing Faculty of Medicine, The University of Hong Kong, Hong Kong, China.

出版信息

J Infect. 2023 Jun;86(6):622-625. doi: 10.1016/j.jinf.2023.02.029. Epub 2023 Feb 22.

DOI:10.1016/j.jinf.2023.02.029
PMID:36822409
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC9943556/
Abstract
摘要

相似文献

1
Molnupiravir and nirmatrelvir-ritonavir reduce mortality risk during post-acute COVID-19 phase.莫努匹拉韦和奈玛特韦-利托那韦可降低新冠后急性期的死亡风险。
J Infect. 2023 Jun;86(6):622-625. doi: 10.1016/j.jinf.2023.02.029. Epub 2023 Feb 22.
2
Molnupiravir and Nirmatrelvir/Ritonavir: The New Available Antiviral Options for COVID-19.莫努匹拉韦和奈玛特韦/利托那韦：新型可用的新冠病毒抗病毒药物选择
Acta Med Indones. 2022 Oct;54(4):638-644.
3
Clinical Outcomes Following Treatment for COVID-19 With Nirmatrelvir/Ritonavir and Molnupiravir Among Patients Living in Nursing Homes.在养老院居住的患者中，使用奈玛特韦/利托那韦和莫努匹韦治疗 COVID-19 的临床结果。
JAMA Netw Open. 2023 Apr 3;6(4):e2310887. doi: 10.1001/jamanetworkopen.2023.10887.
4
Molnupiravir compared to nirmatrelvir/ritonavir for COVID-19 in high-risk patients with haematological malignancy in Europe. A matched-paired analysis from the EPICOVIDEHA registry.在欧洲血液系统恶性肿瘤高危COVID-19患者中，莫努匹韦与奈玛特韦/利托那韦的比较。来自EPICOVIDEHA注册研究的配对分析。
Int J Antimicrob Agents. 2023 Oct;62(4):106952. doi: 10.1016/j.ijantimicag.2023.106952. Epub 2023 Aug 13.
5
Molnupiravir and Nirmatrelvir-Ritonavir: Oral Coronavirus Disease 2019 Antiviral Drugs.莫努匹韦和奈玛特韦-利托那韦：口服冠状病毒病 2019 抗病毒药物。
Clin Infect Dis. 2023 Jan 6;76(1):165-171. doi: 10.1093/cid/ciac180.
6
Association of Molnupiravir and Nirmatrelvir-Ritonavir with reduced mortality and sepsis in hospitalized omicron patients: a territory-wide study.莫努匹韦和奈玛特韦/利托那韦与奥密克戎住院患者死亡率和脓毒症降低的关联：全港范围的研究。
Sci Rep. 2023 May 15;13(1):7832. doi: 10.1038/s41598-023-35068-w.
7
Clinical characteristics of COVID-19 rebound after nirmatrelvir-ritonavir or molnupiravir therapy: A prospective cohort study.奈玛特韦/利托那韦或莫努匹韦治疗后 COVID-19 反弹的临床特征：一项前瞻性队列研究。
Medicine (Baltimore). 2023 Sep 29;102(39):e35094. doi: 10.1097/MD.0000000000035094.
8
Use of Oral Antivirals Ritonavir-Nirmatrelvir and Molnupiravir in Patients with Multiple Myeloma Is Associated with Low Rates of Severe COVID-19: A Single-Center, Prospective Study.口服抗病毒药物利托那韦-奈玛特韦和莫努匹韦在多发性骨髓瘤患者中的使用与 COVID-19 重症率低相关：一项单中心前瞻性研究。
Viruses. 2023 Mar 8;15(3):704. doi: 10.3390/v15030704.
9
Non-randomized evaluation of hospitalization after a prescription for nirmatrelvir/ritonavir versus molnupiravir in high-risk COVID-19 outpatients.高危 COVID-19 门诊患者处方使用奈玛特韦/利托那韦与莫努匹韦后的住院非随机评估。
J Antimicrob Chemother. 2023 Jul 5;78(7):1683-1688. doi: 10.1093/jac/dkad154.
10
Effectiveness of Molnupiravir and Nirmatrelvir-Ritonavir in Hospitalized Patients With COVID-19.莫努匹拉韦和奈玛特韦-利托那韦对COVID-19住院患者的疗效
Ann Intern Med. 2023 Oct;176(10):eL230264. doi: 10.7326/L23-0264.

引用本文的文献

1
Cost-effectiveness Analysis of Nirmatrelvir/Ritonavir for COVID-19 Among Individuals at High Risk: A Modeling Study.奈玛特韦/利托那韦用于高危人群新冠治疗的成本效益分析：一项建模研究
Open Forum Infect Dis. 2025 Mar 26;12(4):ofaf187. doi: 10.1093/ofid/ofaf187. eCollection 2025 Apr.
2
Unlocking insights: Navigating COVID-19 challenges and Emulating future pandemic Resilience strategies with strengthening natural immunity.解锁见解：应对新冠疫情挑战并通过增强自然免疫力效仿未来大流行的韧性策略。
Heliyon. 2024 Jul 17;10(15):e34691. doi: 10.1016/j.heliyon.2024.e34691. eCollection 2024 Aug 15.
3
Nirmatrelvir/ritonavir or Molnupiravir for treatment of non-hospitalized patients with COVID-19 at risk of disease progression.

本文引用的文献

1
Real-world effectiveness of molnupiravir, nirmatrelvir-ritonavir, and sotrovimab on preventing hospital admission among higher-risk patients with COVID-19 in Wales: A retrospective cohort study.在威尔士，使用莫努匹拉韦、奈玛特韦-利托那韦和索特罗维单抗预防 COVID-19 高风险患者住院的真实世界效果：一项回顾性队列研究。
J Infect. 2023 Apr;86(4):352-360. doi: 10.1016/j.jinf.2023.02.012. Epub 2023 Feb 10.
2
Real-world effectiveness of molnupiravir and nirmatrelvir plus ritonavir against mortality, hospitalisation, and in-hospital outcomes among community-dwelling, ambulatory patients with confirmed SARS-CoV-2 infection during the omicron wave in Hong Kong: an observational study.奥密克戎变异株流行期间香港社区居住、活动的经实验室确诊的 2 型严重急性呼吸综合征冠状病毒 2 感染患者中莫努匹韦和奈玛特韦/利托那韦对比死亡率、住院率和住院结局的真实世界疗效：一项观察性研究。
Lancet. 2022 Oct 8;400(10359):1213-1222. doi: 10.1016/S0140-6736(22)01586-0.
3
尼马曲韦/利托那韦或莫努匹韦用于治疗有疾病进展风险的非住院 COVID-19 患者。
PLoS One. 2024 Jun 6;19(6):e0298254. doi: 10.1371/journal.pone.0298254. eCollection 2024.
4
Composite Interventions on Outcomes of Severely and Critically Ill Patients with COVID-19 in Shanghai, China.中国上海针对新型冠状病毒肺炎重症和危重症患者结局的综合干预措施
Microorganisms. 2023 Jul 23;11(7):1859. doi: 10.3390/microorganisms11071859.
Impact of the Use of Oral Antiviral Agents on the Risk of Hospitalization in Community Coronavirus Disease 2019 Patients (COVID-19).口服抗病毒药物的使用对社区新型冠状病毒病 2019 患者（COVID-19）住院风险的影响。
Clin Infect Dis. 2023 Feb 8;76(3):e26-e33. doi: 10.1093/cid/ciac687.
4
Vaccine effectiveness of BNT162b2 and CoronaVac against SARS-CoV-2 Omicron BA.2 infection, hospitalisation, severe complications, cardiovascular disease and mortality in patients with diabetes mellitus: A case control study.BNT162b2和科兴新冠疫苗对糖尿病患者感染新型冠状病毒奥密克戎BA.2、住院、严重并发症、心血管疾病及死亡的疫苗效力：一项病例对照研究
J Infect. 2022 Nov;85(5):e140-e144. doi: 10.1016/j.jinf.2022.08.008. Epub 2022 Aug 17.
5
Effectiveness of BNT162b2 and CoronaVac vaccinations against mortality and severe complications after SARS-CoV-2 Omicron BA.2 infection: a case-control study.BNT162b2 和科兴疫苗对奥密克戎 BA.2 感染后死亡和重症并发症的有效性：一项病例对照研究。
Emerg Microbes Infect. 2022 Dec;11(1):2304-2314. doi: 10.1080/22221751.2022.2114854.
6
Long-COVID treatments: why the world is still waiting.长期新冠的治疗方法：为何全球仍在等待。
Nature. 2022 Aug;608(7922):258-260. doi: 10.1038/d41586-022-02140-w.
7
Safety of an inactivated, whole-virion COVID-19 vaccine (CoronaVac) in people aged 60 years or older in Hong Kong: a modified self-controlled case series.在香港，60 岁及以上人群中使用灭活全病毒 COVID-19 疫苗（科兴疫苗）的安全性：一项修改后的自身对照病例系列研究。
Lancet Healthy Longev. 2022 Jul;3(7):e491-e500. doi: 10.1016/S2666-7568(22)00125-8. Epub 2022 Jul 4.
8
Bell's palsy following vaccination with mRNA (BNT162b2) and inactivated (CoronaVac) SARS-CoV-2 vaccines: a case series and nested case-control study.接种 mRNA（BNT162b2）和灭活（科兴）SARS-CoV-2 疫苗后出现贝尔麻痹：病例系列和巢式病例对照研究。
Lancet Infect Dis. 2022 Jan;22(1):64-72. doi: 10.1016/S1473-3099(21)00451-5. Epub 2021 Aug 16.
9
A living WHO guideline on drugs for covid-19.关于新冠病毒药物的世界卫生组织实用指南。
BMJ. 2020 Sep 4;370:m3379. doi: 10.1136/bmj.m3379.